Key terms
About ACAD
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ACAD news
Apr 22
9:22am ET
Acadia Pharmaceuticals announces Health Canada acceptance of trofinetide NDS
Apr 17
4:07pm ET
Acadia Pharmaceuticals to present trofinetide findings in Rett syndrome at AAN
Apr 09
6:40am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE), Apellis Pharmaceuticals (APLS) and ACADIA Pharmaceuticals (ACAD)
Apr 08
10:40pm ET
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), BioMarin Pharmaceutical (BMRN) and ACADIA Pharmaceuticals (ACAD)
Apr 01
8:46am ET
Largest borrow rate increases among liquid names
Mar 25
8:48am ET
Acadia Pharmaceuticals price target lowered to $25 from $29 at JPMorgan
Mar 15
11:32am ET
Biotech Alert: Searches spiking for these stocks today
Mar 14
11:01am ET
Biotech Alert: Searches spiking for these stocks today
Mar 13
8:46am ET
Acadia Pharmaceuticals price target lowered to $30 from $40 at Morgan Stanley
Mar 12
9:51am ET
Oracle, Dollar General upgraded: Wall Street’s top analyst calls
Mar 12
9:23am ET
Acadia Pharmaceuticals price target lowered to $32 from $36 at Needham
Mar 12
9:18am ET
Acadia Pharmaceuticals price target lowered to $30 from $35 at RBC Capital
Mar 12
8:40am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Incyte (INCY), AbbVie (ABBV) and ACADIA Pharmaceuticals (ACAD)
Mar 12
7:43am ET
Acadia Pharmaceuticals price target lowered to $19 from $25 at Oppenheimer
Mar 12
6:46am ET
Acadia Pharmaceuticals price target lowered to $31 from $40 at Baird
Mar 12
6:35am ET
Acadia Pharmaceuticals price target lowered to $30 from $33 at BofA
Mar 12
6:30am ET
Analysts Are Bullish on Top Healthcare Stocks: ACELYRIN, INC. (SLRN), ZyVersa Therapeutics (ZVSA)
Mar 12
6:22am ET
Acadia Pharmaceuticals price target lowered to $33 from $40 at Canaccord
Mar 12
6:16am ET
Acadia Pharmaceuticals price target lowered to $39 from $44 at JMP Securities
Mar 12
5:55am ET
ACADIA Pharmaceuticals Maintains Buy Rating Despite Price Target Adjustment
Mar 12
5:49am ET
Acadia (NASDAQ:ACAD) Plunges as Pimavanserin Disappoints in Phase 3 Trial
Mar 12
5:37am ET
Acadia Pharmaceuticals price target lowered to $30.19 from $38 at Citi
Mar 12
5:20am ET
Maintaining Hold on ACADIA Pharmaceuticals Amid Clinical Setbacks and Valuation Adjustments
Mar 12
4:45am ET
Acadia Pharmaceuticals downgraded to Neutral from Buy at Mizuho
Mar 12
4:41am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Legend Biotech (LEGN), ACADIA Pharmaceuticals (ACAD) and CytomX Therapeutics (CTMX)
Mar 12
12:40am ET
Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Larimar Therapeutics (LRMR)
Mar 11
4:36pm ET
Acadia Pharmaceuticals falls 20% to $19.32 after resumption of trade
Mar 11
4:35pm ET
Acadia trading resumes
Mar 11
4:17pm ET
Acadia Pharmaceuticals to resume trading at 4:35pm ET
Mar 11
4:13pm ET
Acadia Pharmaceuticals says phase 3 Pimavanserin study did not meet endpoint
Mar 11
4:00pm ET
Acadia trading halted, news pending
Mar 27
10:37am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Acadia Pharmaceuticals Inc. (ACAD) Investigation
Mar 19
8:50am ET
Grabar Law Office Investigates Claims on Behalf of Shareholders of Acadia Pharmaceuticals Inc. (ACAD)
Mar 13
3:22pm ET
Grabar Law Office Investigates Claims on Behalf of Shareholders of Acadia Pharmaceuticals Inc. (ACAD)
Mar 13
7:04am ET
INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
Mar 12
7:02am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
ACAD Financials
Key terms
Ad Feedback
ACAD Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ACAD Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range